Increased vascular access complications in patients with renal dysfunction (full title below)

Journal of Invasive Cardiology

Volumn 22, Issue 1, 2010, Pages 8-13

  Aziz, Emad F ^a   Pulimi, Sandeep ^a   Coleman, Clinton ^b   Florita, Calatin ^c   Musat, Dan ^a   Tormey, Deborah ^a   Fawzy, Ashraf ^a   Lee, Steve ^a   Herzog, Eyal ^a   Coven, David L ^a   Tamis Holland, Jacqueline ^a   Hong, Mun K ^a  

^a Columbia University ^*  (United States)

^b LENOX HILL HOSPITAL   (United States)

^c Good Samaritan Hospital   (United States)

Author keywords

Cardiac catheterization; Closure devices; Kidney disease; Vascular complications

Indexed keywords

ACETYLSALICYLIC ACID; CEFAZOLIN; CLOPIDOGREL; CREATININE; EPTIFIBATIDE; HEPARIN; VANCOMYCIN;

ARTERIOTOMY; ARTERIOTOMY CLOSURE DEVICE; ARTERY DISSECTION; ARTERY THROMBOSIS; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE CLASSIFICATION; FALSE ANEURYSM; FEMORAL ARTERY; HUMAN; INFECTION; INGUINAL REGION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; POSTOPERATIVE COMPLICATION; RETROPERITONEAL HEMATOMA; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; UNIVARIATE ANALYSIS; VASCULAR ACCESS; VASCULAR SURGERY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BACTERIAL INFECTIONS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; EQUIPMENT AND SUPPLIES; EQUIPMENT FAILURE; FEMALE; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HUMANS; INCIDENCE; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 76849094841     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001;134:629-636.
2. Levin A, Djurdjev O, Barrett B, et al. Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am J Kidney Dis 2001;38:1398-1407.
3. Patient mortality and survival. United States Renal Data System. Am J Kidney Dis 1998;32:S69-S80.
4. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121-1129.
5. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001;12:218-225.
6. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-1119.
7. Attallah N, Yassine L, Fisher K, et al. Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin Nephrol 2005;64:412-418.
8. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: The Arterial Revascularization Therapies Study (ARTS). Am Heart J 2005;149:512-9.
9. Koreny M, Riedmuller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: Systematic review and meta-analysis. JAMA 2004;291:350-357.
10. Baim DS, Knopf WD, Hinohara T, et al. Suture-mediated closure of the femoral access site after cardiac catheterization: Results of the suture to ambulate and discharge (STAND I and STAND II) trials. Am J Cardiol 2000;85:864-869.
11. Katz SG, Abando A. The use of closure devices. Surg Clin North Am 2004;84:1267-1280, vi.
12. Eidt JF, Habibipour S, Saucedo JF, et al. Surgical complications from hemostatic puncture closure devices. Am J Surg 1999;178:511-516.
13. Koreny M, Riedmuller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: Systematic review and meta-analysis. JAMA 2004;291:350-357.
14. Nikolsky E, Mehran R, Halkin A, et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: A meta-analysis. J Am Coll Cardiol 2004;44:1200-1209.
15. Gibler WB, Cannon CP, Blomkalns AL, et al. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: A scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation 2005;111:2699-2710.
16. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489S-510S.
17. Kozek-Langenecker SA, Masaki T, Mohammad H, et al. Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int 1999;56:299-305.
18. Dauerman HL, Applegate RJ, Cohen DJ. Vascular closure devices: The second decade. J Am Coll Cardiol 2007;50:1617-1626.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
20. Gault MH, Longerich LL, Harnett JD, et al. Predicting glomerular function from adjusted serum creatinine. Nephron 1992;62:249-256.
21. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S266.
22. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-154.
23. Prevalence of chronic kidney disease and associated risk factors in the United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007;56:161-165.
24. Doyle B, Ting H, Bell M, et al. Major femoral bleeding complications after percutaneous coronary intervention: Incidence, predictors, and Impact on Long-Term Survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Intervent 2008;1:202-209.
25. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047.
26. Deykin D. Uremic bleeding. Kidney Int 1983;24:698-705.
27. Weigert AL, Schafer AI. Uremic bleeding: Pathogenesis and therapy. Am J Med Sci 1998;316:94-104.
28. Von Hoch F, Neumann FJ, Theiss W, et al. Efficacy and safety of collagen implants for haemostasis of the vascular access site after coronary balloon angioplasty and coronary stent implantation. A randomized study. Eur Heart J 1995;16:640-646.
29. Cooper CL, Miller A. Infectious complications related to the use of the Angio-Seal hemostatic puncture closure device. Catheter Cardiovasc Interv 1999;48:301-303.
30. Johanning JM, Franklin DP, Elmore JR, et al. Femoral artery infections associated with percutaneous arterial closure devices. J Vasc Surg 2001;34:983-985.
31. Sohail MR, Khan AH, Holmes DR, Jr., et al. Infectious complications of percutaneous vascular closure devices. Mayo Clin Proc 2005;80:1011-1015.
32. Haag-Weber M, Horl WH. Uremia and infection: Mechanisms of impaired cellular host defense. Nephron 1993;63:125-131.
33. Clarke IA, Ormrod DJ, Miller TE. Host immune status in uremia. V. Effect of uremia on resistance to bacterial infection. Kidney Int 1983;24:66-73.
34. Cherr GS, Travis JA, Ligush J Jr, et al. Infection is an unusual but serious complication of a femoral artery catheterization site closure device. Ann Vasc Surg 2001;15:567-570.
35. Baddour LM, Bettmann MA, Bolger AF, et al. Nonvalvular cardiovascular device-related infections. Circulation 2003;108:2015-2031.
36. Muller DW, Shamir KJ, Ellis SG, et al. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol 1992;69:63-68.
37. Duffin DC, Muhlestein JB, Allisson SB, et al. Femoral arterial puncture management after percutaneous coronary procedures: A comparison of clinical outcomes and patient satisfaction between manual compression and two different vascular closure devices. J Invasive Cardiol 2001;13:354-362.
38. Gonze MD, Sternbergh WC 3rd, Salartash K, et al. Complications associated with percutaneous closure devices. Am J Surg 1999;178:209-211.
39. Tavris DR, Gallauresi BA, Lin B, et al. Risk of local adverse events following cardiac catheterization by hemostasis device use and gender. J Invasive Cardiol 2004;16:459-464.
40. Applegate RJ, Sacrinty M, Kutcher MA, et al. Vascular complications with newer generations of angioseal vascular closure devices. J Interv Cardiol 2006;19:67-74.
41. Resnic FS, Blake GJ, Ohno-Machado L, et al. Vascular closure devices and the risk of vascular complications after percutaneous coronary intervention in patients receiving glycoprotein IIb-IIIa inhibitors. Am J Cardiol 2001;88:493-496.
42. Dangas G, Mehran R, Kokolis S, et al. Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. J Am Coll Cardiol 2001;38:638-641.
43. Cura FA, Kapadia SR, L'Allier PL, et al. Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. Am J Cardiol 2000;86:780-782, A9.
44. Applegate RJ, Sacrinty MT, Kutcher MA, et al. Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention 1998-2003. Catheter Cardiovasc Interv 2006;67:556-562.
45. Tavris D, Gross T, Gallauresi B, et al. Arteriotomy closure devices-the FDA perspective. J Am Coll Cardiol 2001;38:642-644.
46. Vaitkus PT. A meta-analysis of percutaneous vascular closure devices after diagnostic catheterization and percutaneous coronary intervention. J Invasive Cardiol 2004;16:243-246.
47. Exaire JE, Dauerman HL, Topol EJ, et al. Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices. Am Heart J 2004;147:31-34.
48. Chevalier B, Lancelin B, Koning R, et al. Effect of a closure device on complication rates in high-local-risk patients: Results of a randomized multicenter trial. Catheter Cardiovasc Interv 2003;58:285-291.